|
May 7, 2024
|
Biora Therapeutics to Report First Quarter 2024 Financial Results and Provide Corporate Update
|
|
May 6, 2024
|
Biora Therapeutics to Present Clinical Data on Device Function of the NaviCap™ Oral Delivery Platform at Digestive Disease Week 2024
|
|
April 30, 2024
|
Biora Therapeutics Announces Completion of Multiple-Ascending Dose (MAD) Cohorts for Clinical Trial of BT-600
|
|
April 8, 2024
|
Biora Therapeutics Announces New Patent Covering its BioJet™ Liquid Jet Delivery Technology
|
|
April 4, 2024
|
Biora Therapeutics Achieves Positive Interim Results for Clinical Trial of BT-600, Advancing NaviCap™ Platform Development
|
|
April 3, 2024
|
Biora Therapeutics Announces Closing of $6 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
|
|
April 1, 2024
|
Biora Therapeutics Announces $6 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
|
|
March 26, 2024
|
Biora Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results
|
|
March 18, 2024
|
Biora Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update
|
|
March 11, 2024
|
Biora Therapeutics Further Reduces Net Debt and Monetizes Legacy Asset
|